Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO

Key Points

• Bone mineral density changes signify important health implications for patients with cystic fibrosis, especially with long-term treatment.
• After starting elexacaftor-tezacaftor-ivacaftor, patients showed notable changes in bone mineral density across youth and adults.
• Observational analysis reveals these changes, indicating a potential benefit from the intervention on bone health.
• Further evaluation is needed to understand the long-term impact of this intervention on overall bone health.